Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 15/20 | 0.65 |
| ▸ | JAK2 | O60674 | 7/20 | 0.53 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.49 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.49 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.49 |
| ▸ | JAK1 | P23458 | 2/20 | 0.46 |
| ▸ | PPARG | P37231 | 3/20 | 0.46 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1706239 | 0.92 | TYK2 (0.64) | TYK2JAK2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL1706019 | 0.85 | TYK2 (0.55) | TYK2JAK2JAK1 | |
| SCHEMBL3517558 | 0.85 | TYK2 (0.70) | TYK2JAK2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL3515207 | 0.85 | TYK2 (0.65) | TYK2JAK2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL1706164 | 0.83 | TYK2 (0.52) | TYK2JAK2JAK1 | |
| SCHEMBL21056025 | 0.82 | PPARG (0.66) | TYK2JAK2JAK1PPARGGRM4 | |
| SCHEMBL1707688 | 0.82 | TYK2 (0.70) | TYK2JAK2JAK1 | |
| SCHEMBL1706538 | 0.82 | TYK2 (0.63) | TYK2JAK2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL1706693 | 0.80 | TYK2 (0.49) | TYK2JAK2JAK1 | |
| SCHEMBL1706158 | 0.79 | TYK2 (1.00) | TYK2JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8486950-B2 | Janus kinase inhibitor compounds and methods | F. HOFFMANN-LA ROCHE AG (CH) | 2013-07-16 | — | — | US | disclosed |
| EP-2440529-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | F. Hoffmann-La Roche AG (CH) | 2012-04-18 | — | — | EP | disclosed |
| WO-2010142752-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-16 | — | — | WO | disclosed |
| US-20100317643-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317643-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | TYK2 21/4885JAK2 1/4885TAS1R3 1766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.